Sugar Editorial Picks
Aug 26, 2008 -
If you pass the occasional pill to your friends, you are not alone. According to a recent study published in The Journal of Women’s Health, sharing prescription drugs is common among young adults, especially 18- to 44-year-old women. The recent survey of 25,000 people found that more than one-third of the women polled shared prescription drugs with friends or took pills from their pals.
- 24 Comments
Other Search Results
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Symptoms
- Screening Tests
- Treatment
- Lifestyle Changes
- Medications
- Long-Term Complications
- Emergency Complications
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approvals
- Sitagliptin (Januvia), the first in a new class of diabetes drugs called DPP-4 inhibitors, was approved in 2006.
- Janumet, a 2-in-1 pill that contains both sitagliptin and metformin, was approved in 2007.
- These drugs are taken by mouth and may be more convenient for patients than exenatide (Byetta), a similar drug. DPP-4 inhibitors do not cause weight gain and may pose a lower risk for hypoglycemia than some other diabetes drugs.
Drug Safety Alert
Rosiglitazone (Avandia) may significantly increase the risk for heart attack, indicates a review published in the Journal of the American Medical Association. In 2007, a panel of experts from the Food and Drug Administration (FDA) agreed the drug increases the risk of heart attacks -- but concluded it should remain on the market.
- 4 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Causes
- Prognosis
- Diagnosis
- Treatment
- Medications
- Other Treatments
- Therapy and Lifestyle Chang...
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the FDA approved risperidone (Risperdal) for short-term treatment of manic or mixed episodes of bipolar I disorder in children ages 10 - 17. Risperidone (an atypical antipsychotic) and lithium (a mood stabilizer) are the two drugs currently approved for treating pediatric patients with bipolar disorder.
Drug Warnings
- Olanzapine (Zyprexa, Symbex) causes a greater risk for high blood sugar than other atypical antipsychotics, according to updated information added to the drug’s warning label.
- 1 Comment
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Symptoms
- Complications
- Diagnosis
- Treatment
- Medications
- Surgery
- Lifestyle Changes
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Treatment Approaches
- Patients with rheumatoid arthritis who do not respond to single-drug therapy often do better when a combination of drugs is used, indicates a review of 23 clinical trials published in 2007 in the Annals of Internal Medicine. However, the researchers were unable to determine which combinations of drugs work best or which individual drugs are more effective than others.
- Combination drug treatment is now becoming a standard approach to treating rheumatoid arthritis while it is still in its early stages. Another 2007 Annals of Internal Medicine study indicated that initial combination therapies slow progression of joint damage more rapidly than single-drug therapy but, after several years, all treatment strategies produce benefits.
Fish Oil for Joint Pain
The omega-3 fatty acids found in fish oil may have anti-inflammatory properties that can help relieve joint pain, indicates a 2007 review in Pain.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Causes
- Diagnosis
- Other Disorders Associated ...
- Complications
- Treatment
- Medications
- Behavioral Management
- Other Treatments
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the Food and Drug Administration (FDA) approved lisdexamfetamine (Vysvanse), a new stimulant drug for the treatment of attention-deficit/hyperactivity disorder (ADHD). The active ingredient in lisdexamfetamine is similar to dextroamphetamine, the drug used in Dexedrine and Adderall.
Drug Warning
In 2007, the FDA instructed the manufacturers of all ADHD drugs to include drug warning labels describing the risks for heart and psychiatric side effects.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Lifestyle or Psychological ...
- Physical Causes
- Prognosis
- Diagnosis
- Treatment
- Lifestyle Changes
- Medications
- Injections or Topical Treat...
- Other Treatments
- Natural Remedies
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
FDA Warns about Dietary Supplements
In 2006 and 2007, the FDA issued numerous warnings about “natural” dietary supplements promoted for erectile dysfunction and sexual enhancement. These products -- marketed under names such as “True Man,” “Energy Max,” “Rhino Max”-- contain illegal substances that can interact with prescription drugs and dangerously lower blood pressure. The interaction risks are greatest for men with diabetes, high blood pressure, high cholesterol, or heart disease who take prescription drugs that contain nitrates.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Symptoms
- Risk Factors
- Prognosis
- Diagnosis
- Treatment
- Other Treatments
- Decongestants
- Antihistamines
- Corticosteroids
- Immunotherapy
- Prevention
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
Ciclesonide (Omanaris), a corticosteroid nasal spray, has been approved for treatment of seasonal and perennial allergic rhinitis (hay fever) in adults and children age 12 years and older.
FDA Drug Warnings
- The antihistamine promethazine (Phenergan) should not be given to children younger than age 2 because it may cause serious breathing problems.
- Omalizumab (Xolair) may cause a life-threatening allergic reaction (anaphylaxis). This drug is used to treat allergy-related asthma, but is also being investigated as an allergy treatment.
Cough and Cold Medicines for Children
In 2007, the FDA began reviewing the safety and effectiveness of cough and cold medicines for children.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Diagnosis
- Causes
- Risk Factors
- Complications
- Symptoms
- Treatment
- Lifestyle Changes
- Medications
- Classes of Medications
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the FDA approved a new type of high blood pressure drug. Aliskiren (Tekturna) blocks renin, a kidney enzyme that is associated with blood pressure regulation. Aliskiren can be taken alone or in combination with other blood pressure drugs, but it should not be used during pregnancy.
- 1 Comment
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Symptoms
- Complications
- Barrett's Esophagus
- Diagnosis
- Treatment
- Prevention
- Medications
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
New Research
- Obesity and GERD. Increased weight in women is linked to more frequent GERD symptoms, according to the Nurses' Health Study, which included 10,545 female participants. Overweight and obese women were two to three times more likely to have frequent symptoms than women of normal weight.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Symptoms
- Complications
- Diagnosis
- Prevention
- Treatment for Acute Sinusit...
- Treatment for Chronic Sinus...
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Restriction
In February 2007, the FDA announced that the antibiotic telithromycin (Ketek) should no longer be used for treatment of acute bacterial sinusitis. In June 2006, the FDA reported that several people had died of liver damage after taking this drug. Telithromycin is now only approved for treatment of community-acquired pneumonia.
- 0 Comments